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Abstract 
Given the role of mitochondria in oxygen consumption, metabolism and cell death regulation, alterations in mito‑
chondrial function or dysregulation of cell death pathways contribute to the genesis and progression of cancer. 
Cancer cells exhibit an array of metabolic transformations induced by mutations leading to gain‑of‑function of 
oncogenes and loss‑of‑function of tumor suppressor genes that include increased glucose consumption, reduced 
mitochondrial respiration, increased reactive oxygen species generation and cell death resistance, all of which ensure 
cancer progression. Cholesterol metabolism is disturbed in cancer cells and supports uncontrolled cell growth. In par‑
ticular, the accumulation of cholesterol in mitochondria emerges as a molecular component that orchestrates some 
of these metabolic alterations in cancer cells by impairing mitochondrial function. As a consequence, mitochondrial 
cholesterol loading in cancer cells may contribute, in part, to the Warburg effect stimulating aerobic glycolysis to 
meet the energetic demand of proliferating cells, while protecting cancer cells against mitochondrial apoptosis due 
to changes in mitochondrial membrane dynamics. Further understanding the complexity in the metabolic alterations 
of cancer cells, mediated largely through alterations in mitochondrial function, may pave the way to identify more 
efficient strategies for cancer treatment involving the use of small molecules targeting mitochondria, cholesterol 
homeostasis/trafficking and specific metabolic pathways.
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Introduction
Cancer cells exhibit critical metabolic transforma-
tions induced by mutations leading to gain-of-function 
of oncogenes and loss-of-function of tumor suppres-
sor genes that result in cell deregulation associated 
with increased cellular stress. Hanahan and Weinberg 
identified the six conceptual hallmarks of human can-
cer: (1) self-sufficient growth signaling, (2) evasion of 
growth suppressors, (3) cell death resistance, (4) replica-
tive immortalization, (5) angiogenesis and (6) invasion/
metastasis [1]. Other common characteristics of cancer 
cells include enhanced anabolism, avoidance of immune 
destruction and altered autophagy [2, 3]. Of these charac-
teristic features of cancer cells, mitochondria are directly 
involved in a number of them. Indeed, mitochondria are 
critical mediators of apoptosis and the source of reactive 
oxygen species (ROS) generation and energy production. 
Consequently, altered mitochondrial function of cancer 
cells underlies several phenotypes, including: (1) resist-
ance to apoptosis; (2) increased biosynthetic anabolism 
to support uncontrolled growth and proliferation; (3) 
increased ROS generation that activates metastatic pro-
teases, tumor-promoting inflammation, genetic instabil-
ity and DNA mutagenesis; (4) decreased mitochondrial 
oxidative phosphorylation (OXPHOS), increased aerobic 
glycolysis and decrease of pH in the extracellular milieu. 
Furthermore, due to its role as a hub in several signal-
ing pathways [4], mitochondria are central for key met-
abolic alterations of cancer cells, some of which will be 
described below.
Experimental evidence indicates that high cell prolif-
eration [5, 6] and tumor growth [7, 8] are closely asso-
ciated with enhanced cholesterol requirement. Some 
types of cancers, such as hepatocellular carcinoma 
(HCC), are dependent on cholesterol for growth [9], 
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and observational studies show a protective association 
between the use of statins and the risk of developing liver 
cancer [10], although this trend has been also observed in 
other cancer types, such as prostate and gastrointestinal 
cancers [11]. In line with this, genome-scale metabolic 
models of hepatocellular carcinoma found that among 
101 metabolites relevant to HCC development, 30  % of 
them are related to cholesterol biosynthesis [12]. This 
protective effect of statins has been attributed to the inhi-
bition of the mevalonate pathway (see below), prevent-
ing the posttranslational modification of the oncogenes 
MYC, RAS and RHO [11, 13, 14]. Moreover, analyses of 
the Cancer Genome Atlas (TCGA) database revealed a 
correlation between increased activity of the cholesterol 
synthesis pathway and decreased survival in patients with 
sarcoma, acute myeloid leukemia and melanoma [15, 
16], supporting the concept that cholesterol promotes 
carcinogenesis. In this regard, cholesterol trafficking to 
mitochondria has been reported in tumor cells [17, 18] 
and may account for the recognized mitochondrial dys-
function and contribute to chemotherapy and apoptosis 
resistance and metabolic reprogramming of cancer cells, 
which will be discussed in the following sections.
Mitochondria in cell life and death
Life‑sustaining functions
Mitochondria are complex organelles, which differ from 
the often-held view of isolated, small rounded double-
membrane structures. They constitute a dynamic net-
work that continuously undergoes fusion and fission 
controlled by specific mechanisms [19], and have inter-
actions with other cell structures such as cytoskeleton 
and endoplasmic reticulum (ER) [20, 21]. Mitochondria 
contain multiple copies of their own maternally-inher-
ited mitochondrial DNA (mtDNA), with an epigenetic 
complexity not completely understood [22]. Mitochon-
drial DNA is a circular molecule of approximately 16.5 
kilobases present from hundreds to thousands of copies 
per cell, which encodes 13 polypeptides of the OXPHOS 
and respiratory chain, as well as 2 ribosomal RNAs and 
22 transfer RNAs necessary for translation of polypep-
tides inside mitochondria. Most mitochondrial proteins 
(approximately 1500) are encoded by nuclear DNA, 
translated in the cytosol and imported into the mito-
chondria through specific translocator complexes (TIM 
and TOM) of the mitochondrial inner (MIM) and outer 
membranes (MOM), respectively. In addition, a disulfide 
relay molecular device consisting of MIA40 and aug-
menter of liver regeneration (ALR) are responsible for the 
import of nuclear encoded sulfur Fe/S cluster proteins to 
the mitochondrial intermembrane space that are essen-
tial for mitochondrial function [23, 24]. Recent data have 
shown that ALR links mitochondrial function to HCC 
development [25, 26]. Indeed, mitochondrial proteome 
has significant cell-type differences, allowing mitochon-
dria to serve in a highly adaptive fashion to the cellular 
specific functional requirements [27].
Mitochondria are the power plants of the cell, provid-
ing the energy for countless cellular functions through 
OXPHOS. OXPHOS is coordinated by a cascade of redox 
reactions organized in five protein complexes embed-
ded in the MIM, known as the electron transport chain 
(ETC), which transfers electrons to oxygen [28, 29]. The 
fall in electron potential energy through the ETC is used 
to pump protons out of the mitochondrial matrix to the 
intermembrane space, generating an electrochemical 
gradient known as the mitochondrial transmembrane 
potential (Δψm), which induces a proton motive force 
used by complex V to regenerate ATP from ADP. Moreo-
ver, many additional mitochondrial processes, especially 
those related to transport of solutes across the MIM [30] 
are dependent on the electrochemical driving force of 
the Δψm. Additional metabolic pathways that are located 
within mitochondria comprise the tricarboxylic acid 
cycle (TCA or Krebs cycle), β-oxidation of fatty acids, 
steroidogenesis, metabolism of amino acids, formation 
of Fe/S clusters, heme biosynthesis as well as reactions 
involved in lipogenesis, gluconeogenesis, ketogenesis and 
ammonium detoxification (urea cycle) [31].
Physiologically under aerobic conditions, cells degrade 
glucose via glycolysis to pyruvate, which is imported 
into mitochondria. Pyruvate enters the TCA cycle in the 
form of acetyl-CoA that along with oxaloacetate gener-
ates citrate, in a reaction catalyzed by citrate synthase. 
Citrate is processed in the TCA cycle to generate reduc-
ing equivalents that feed the ETC and generate energy 
with the consumption of oxygen. However, in conditions 
where macromolecular biosynthesis is active, citrate may 
be exported to cytosol where is converted to acetyl-CoA 
by ATP citrate lyase (ACLY), which is used for lipogen-
esis. Besides their role in metabolism, mitochondria are 
involved in calcium homeostasis, innate immunity, inte-
gration of signaling pathways and autophagy [32, 33]. 
Moreover, in response to metabolic and genetic stress 
mitochondria and nucleus engage in bidirectional signal-
ing pathways, which modulate cell function [4, 34, 35].
Electron transport through the ETC can leak the chain 
and react with oxygen to generate ROS [36, 37]. Complex 
I and complex III are the major sources of mitochondrial 
ROS generation [28], although other mitochondrial sites 
also contribute to ROS production, including complex 
II [38]. The existence of an efficient antioxidant defense 
system, of which mitochondrial glutathione (mGSH) 
is a central component, prevents or repairs oxidative 
damage generated during normal aerobic metabolism 
[39]. The primary ROS generated in mitochondria is 
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superoxide [40], which is produced in the mitochondrial 
matrix and undergoes dismutation to hydrogen perox-
ide (H2O2) [40], a reaction catalyzed by mitochondrial 
superoxide dismutases (SOD2). Hydrogen peroxide is 
further inactivated by the mitochondrial glutathione per-
oxidase (mGSH/GPX) and peroxiredoxin/thioredoxin 
(Prx/Trx) antioxidant systems [41]. Both systems use the 
reducing equivalents of NADPH to regenerate the mito-
chondrial oxidized glutathione (mGSSG) and Trx back 
to the reduced forms. The Prx/Trx system is thought 
to be responsible for scavenging hydrogen peroxide at 
nanomolar concentrations, while mGSH/GPX system is 
important for buffering high ROS levels [42, 43]. How-
ever, both systems are mutually regulated, as selective 
depletion of mGSH results in decreased levels of Trx2 
and Prx3 [44], highlighting the central role of mGSH in 
maintaining an adequate hydrogen peroxide homeosta-
sis. Due to its more stable and diffusible nature, hydro-
gen peroxide acts as a second messenger because of its 
reactions with specific oxidation-prone protein cysteinyl 
residues [45], which confers properties to hydrogen per-
oxide as a mitochondrial signaling molecule [4]. In line 
with this, mitochondrial hydrogen peroxide bursts have 
self-sustained circadian oscillations, acting as a redox 
intracellular pacemaker [46].
Death promoting pathways
Besides their fundamental role in energy generation, 
mitochondria also play a strategic role in the regulation 
of several forms of cell death, including apoptosis (both 
caspase-dependent and independent), necrosis and pro-
grammed necrosis [47]. The central mediators of apopto-
sis include a group of cysteine proteases named caspases, 
which become activated by a proteolytic processing cas-
cade in response to pro-apoptotic signals. The series of 
events leading to apoptosis have been categorized in two 
modes, the extrinsic and intrinsic apoptotic pathways. 
The extrinsic pathway involves extracellular ligand bind-
ing to a transmembrane death receptor, such as TNF 
receptor or FAS receptor, followed by recruitment of 
cytosolic adaptor proteins and activation of an initiator 
caspase (usually caspase-8), which stimulates an effector 
caspase (such as caspase-3). Conversely, the intrinsic (or 
mitochondrial) pathway involves the destabilization of 
the MOM and the release of mitochondrial proteins that 
activate effector caspases. The BCL-2 family of proteins 
regulates this pathway with opposing pro-apoptotic effec-
tor functions (BAX, BAK), pro-apoptotic BH3-only pro-
teins (BAD, BIM, BID, BIK, Noxa, PUMA, HRK, BMF) 
and anti-apoptotic functions (BCL-2, BCL-xL, MCL-1, 
A1, BCL-B, BCL-w) [48]. Activation of the intrinsic path-
way of apoptosis by a number of stimuli and stresses, trig-
gers the binding and activation of pro-apoptotic proteins 
BAX or BAK to the MOM leading to the MOM per-
meabilization (MOMP) without disruption of the inner 
membrane and the subsequent release of proteins from 
the mitochondrial intermembrane space (IMS), such as 
cytochrome c [49, 50]. Although active BAX or BAK are 
required to induce MOMP, the underlying mechanism 
is controversial [51]. While the model of pro-apoptotic 
activation or neutralization by anti-apoptotic members 
are still incompletely known, recent findings have shown 
that BCL-2 ovarian killer (BOK), which displays a high 
sequence similarity to BAX and BAK, engages the mito-
chondrial apoptotic pathway independently of BAK/
BAX [52]. Although mitochondrial proteins are normally 
secured in the IMS the rupture of the physical barrier 
(MOM) constitutes a point-of-no-return in cell death 
[49, 50]. Pro-apoptotic BH3-only proteins act as stress 
sentinels that relay the diverse array of apoptotic signals 
via BAX/BAK activation to induce MOMP. In contrast, 
anti-apoptotic BCL-2-family proteins prevent MOMP 
and apoptosis by binding BH3-only proteins, preventing 
their interaction with BAX/BAK, or by binding activated 
BAX/BAK [53]. Pro- and anti-apoptotic BCL-2 protein 
interactions are mediated between BH-3 domains and 
the BH3 binding cleft in anti-apoptotic BCL-2 proteins.
Once released from the mitochondria into the cytosol 
through MOMP, cytochrome c binds to the adaptor mol-
ecule APAF-1, causing it to oligomerise and form a hep-
tameric structure called apoptosome [54]. This complex 
recruits pro-caspase 9, which in turn, activates the execu-
tioner caspases-3 and -7, triggering the cascade of events 
that lead to controlled cell death and fragmentation. In 
addition to cytochrome c, other IMS proteins (Table  1) 
are also mobilized and released into the cytosol following 
MOMP where they promote or counteract caspase acti-
vation and hence cell death [55–60].
Table 1 IMS proteins related to apoptosis induction
IMS protein MW (kDa) Function References












AIF 62 DNA fragmentation [56, 59]
ENDOG 28 DNA fragmentation [55]
AK2, Adenylate  
Kinase 2
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For the execution of mitochondrial apoptosis 
cytochrome c detaches from the MIM and dissoci-
ates from the phospholipid cardiolipin, which binds 
cytochrome c by an electrostatic bond [61]. Cardi-
olipin can be oxidized by ROS or by the cardiolipin–
cytochrome c complex [62] resulting in oxidized 
cardiolipin, which exhibits lower affinity for cytochrome 
c than the reduced form, and therefore contributes to 
cytochrome c detachment from MIM and its release to 
cytosol. Since mitochondrial ROS are controlled by anti-
oxidants [63, 64], mGSH arises as an important modula-
tor of apoptotic cell death by indirectly controlling the 
redox state of cardiolipin [63, 65]. In addition, it has been 
described that oxidized cardiolipin modulates the bio-
physical properties of MOM to allow oligomerized BAX 
to insert and permeabilize the MOM [63, 65, 66].
Integrin-mediated attachment of normal cells to 
the extracellular matrix elicits anti-apoptotic and pro-
survival signaling. The loss of cell–matrix interaction 
induces anoikis, a specific form of apoptosis [67]. Cell 
detachment leads to upregulation and activation of sev-
eral BH3-only pro-apoptotic proteins (BID, BIM and 
BDF) that, in turn, activate BAX and BAK resulting in 
MOMP and the apoptotic cascade, resulting in cell death 
[68]. In addition to MOMP, the generation of mitochon-
drial ROS in cells undergoing anoikis is required for cell 
death, as antioxidants treatment suppressed anoikis [69, 
70]. Normal cells detached from the matrix undergo 
dramatic global metabolic changes characterized by 
decreased mitochondrial respiration and SOD2 induc-
tion. Indeed, cells depleted of SOD2 are hypersensitive 
to cell death by anoikis [71], suggesting the importance 
of ROS generated in mitochondria in the execution of 
anoikis.
As opposed to apoptosis, necrosis is a morphologically 
distinct form of cell death responsible for irreversible 
tissue destruction due to bioenergetic failure and oxida-
tive damage. Permeabilization of the MIM by the mito-
chondrial permeability transition (MPT) and secondary 
rupture of the MOM is a key event of necrosis. MPT 
is a regulated pore-forming protein complex whose 
molecular characterization remains elusive [72–74]. Of 
the MPT components, cyclophillin D is a key constitu-
ent, while the role of other putative components, such 
as voltage-dependent anion channel (VDAC), adenine 
nucleotide translocase (ANT) and translocator protein 
(TSPO, also called benzodiazepine receptor, PBR) is con-
troversial [49, 75, 76]. Mitochondrial ROS regulate MPT 
by targeting specific cyclophillin D cysteine residues. 
Necrosis is characterized by mitochondrial swelling, loss 
of Δψm, and impaired OXPHOS and ATP generation. 
The fundamental difference with respect to apoptosis 
is the rapid loss of cellular membrane potential due to 
energy depletion and ion pump/channel failure, leading 
to swelling and cytolysis. Concomitantly, water influx 
causes matrix swelling, rupture of MOM and release of 
apoptogenic proteins sequestered in IMS. These events, 
however, block apoptotic cell death due to energetic fail-
ure, ATP exhaustion and oxidative stress-mediated cas-
pase inactivation. Moreover, TNFα has been recently 
shown to induce a caspase-independent form of pro-
grammed cell death, named programmed necrosis or 
necroptosis [77, 78], involving receptor-interacting ser-
ine/threonine-protein kinase 1 (RIPK1) and RIPK3 
kinases, which interact with the pseudokinase mixed lin-
eage kinase domain-like protein (MLKL). The execution 
of necroptosis requires mitochondrial ROS generation, 
which is dependent of MPT and involves cyclophyllin D 
but it is independent of BAX or BAK [79].
Cholesterol homeostasis and mitochondrial 
trafficking
Cholesterol synthesis and deregulation in cancer cells
Cholesterol is an essential component of membrane bilay-
ers that plays a key role in their integrity and function. 
While intake of cholesterol from the diet ends up in dif-
ferent cell membranes, the predominant mechanism that 
provides the cholesterol needed for cellular functions is its 
de novo synthesis from acetyl-CoA in the so-called meva-
lonate pathway, which generates not only cholesterol but 
also non-sterol components, such as dolichol, ubiquinol 
and isoprenoids. The hydroxymethylglutaryl-CoA reduc-
tase (HMGCoAR) catalyzes the reduction of HMG CoA 
to mevalonate, the rate-limiting step in the synthesis of 
cholesterol [80]. Mevalonate is phosphorylated to pyroph-
osphomevalonate, which is then converted to isopentenyl 
pyrophosphate (IPP). IPP can be reversibly transformed 
to dimethylallylpyrophosphate (DMAPP), which can 
combine with IPP to generate the 10-carbon isoprenoid 
geranyl pyrophosphate (GPP). The secuential addition of 
1 or 2 more IPP units to GPP generates farnesyl pyroph-
osphate (FPP) and geranylgeranyl pyrophosphate (GGPP), 
respectively. Isoprenoids generation in the mevalonate 
pathway is an essential mechanism of posttranslational 
modification of proteins and these lipid moieties anchor 
target proteins to cell membranes. FPP is used to pre-
nylate proteins of the Ras family, while GGPP prenylates 
those of the Rho family [81]. In addition, FPP can be con-
verted into squalene by squalene synthase (SS), which 
catalyzes the first step in the committed pathway for 
cholesterol synthesis. Statins, whose chemical structure 
is similar to that of HMGCoA, compete with and inhibit 
HMGCoAR, preventing the formation of mevalonate and 
its downstream product IPP. Therefore, the therapeutic 
effects of statins can extend beyond cholesterol inhibition 
and impact in the regulation of a number of proteins due 
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to the blockade of isoprenoids (FPP and GGPP) genera-
tion. In contrast to statins, the inhibition of SS results in 
selective cholesterol downregulation without exerting a 
major effect in the isoprenylation of proteins [82].
As HMGCoAR is the regulatory enzyme in the meva-
lonate pathway its feedback and transcriptional control 
impact in cholesterol and isoprenoids regulation. One 
mechanism for feedback control involves the rapid degra-
dation of HMGCoAR mediated by ER resident proteins, 
Insigs. Accumulation of sterols in the ER membrane trig-
gers binding of the membrane domain of HMGCoAR to 
a subset of Insigs, which carry a membrane-anchored 
ubiquitin ligase called GP78 which ubiquitinates HMG-
CoAR, marking it for proteasomal degradation [83]. 
HMGCoAR is regulated at the transcriptional level by 
the transcription factor SREBP-2, which resides in the ER 
is an inactive form. When sterols levels are low, SREBP-2 
is transported from the ER to the Golgi to undergo a pro-
teolytic processing by specific proteases, resulting in the 
mature form of SREBP-2, which translocates to the nuclei 
to induce HMGCoAR as well as other targets involved in 
the regulation of cholesterol homeostasis, including the 
LDL receptor.
As cholesterol synthesis requires oxygen, which is used 
for the biotransformation of squalene to cholesterol, an 
additional mechanism that regulates cholesterol synthe-
sis is oxygen availability. Indeed, the bulk for the oxygen 
requirement centers on the sequential transformation of 
lanosterol to cholesterol, involving several redox reac-
tions. Moreover, hypoxia has been shown to stimulate 
HMGCoAR degradation through both accumulation of 
lanosterol and Insigs induction [84]. In contrast to these 
physiological features, cholesterol synthesis and regula-
tion are altered at several levels in cancer cells to meet 
the unrestricted growth needs [84–87]. Indeed, tumor 
cells exhibit increased cholesterol levels compared to sur-
rounding cells; moreover, cancer tissues display increased 
upregulation of HMGCoAR, loss of feedback inhibi-
tion, decreased expression of cholesterol exporter ATP 
binding cassette transporter A1 (ABCA1) and increased 
extracellular cholesterol uptake via LDL receptor [87]. 
Hence, as briefly described below (“Strategies targeting 
the mevalonate pathway and cholesterol synthesis in can-
cer” section), targeting the mevalonate pathway may be 
of potential relevance in cancer therapy.
Mitochondrial cholesterol trafficking in cancer
Mitochondria are cholesterol-poor organelles com-
pared to other cell bilayers (e.g. plasma membrane). 
Nevertheless, the limited availability of cholesterol in 
the MIM plays an important physiological role, includ-
ing the synthesis of bile acids in hepatocytes or steroid 
hormones in specialized tissues through the metabolism 
of mitochondrial cholesterol by CYP27A or CYP11A1, 
respectively. In pathological conditions, however, the 
accumulation of cholesterol in mitochondria alters mem-
brane organization and the coexistence of lipid-disordered 
and lipid-ordered phases, which regulates membrane per-
meability and function of resident proteins [88]. Of rel-
evance, increased mitochondrial cholesterol levels have 
been described in solid tumors. For instance, mitochon-
drial cholesterol levels of tumors from Buffalo rats bearing 
transplanted Morris hepatomas are two to fivefold higher 
than the content found in mitochondria prepared from 
host liver, and correlated with the degree of tumor growth 
and malignancy [89, 90]. As mitochondrial cholesterol in 
cancer cells contribute to the alterations in mitochondrial 
function and properties, understanding the mechanisms 
governing the trafficking of cholesterol to mitochon-
dria may be of relevance in cancer cell biology. In this 
regard, given its lipophilic properties and water insolubil-
ity, non-vesicular transport by specific carriers stands as 
the major mechanism of cholesterol transport between 
organelles. In particular, mitochondrial cholesterol trans-
port is preferentially regulated by the steroidogenic acute 
regulatory domain 1 (StARD1), the founding member of 
a family of lipid transporting proteins that contain StAR-
related lipid transfer (START) domains [91]. StARD1 is a 
MOM protein, which was first described and best char-
acterized in steroidogenic cells, where it plays an essen-
tial role in cholesterol transfer to MIM for metabolism 
by CYP11A1 to generate pregnenolone. Despite similar 
properties with StARD1, other StART members cannot 
replace StARD1, as germline StARD1 deficiency is lethal 
due to adrenocortical lipoid hyperplasia [92]. Moreover, 
targeted mutations in MLN64 (StARD3), another START 
member with wide tissue distribution, impair steroido-
genesis while causing minor alteration in cholesterol 
metabolism [93]. Furthermore, analyses of the TCGA 
database further support a role for StARD1 and MLN64 
and subsequent mitochondrial cholesterol enrichment in 
cancer development. Although MLN64 is an endosomal 
protein, it participates in the egress of cholesterol from 
endosomes to mitochondria [94], suggesting that MLN64 
and StARD1 work in concert to ensure the trafficking of 
cholesterol to MIM. Increased StARD1 expression and 
mitochondrial cholesterol loading are causally linked as 
StARD1 silencing decrease mitochondrial cholesterol lev-
els in hepatocellular carcinoma [17]. Moreover, decreased 
ABCA1 activity has been reported in colorectal cancer 
cells either through loss-of-function or gene downregu-
lation and ABCA1 downregulation promoted cancer cell 
survival by increased mitochondrial cholesterol accu-
mulation [95]. Thus, these findings indicate that the traf-
ficking and accumulation of cholesterol in mitochondria 
is a characteristic feature of many types of cancer and its 
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role in carcinogenesis may be related to the regulation of 
cell death and chemotherapy sensitization, which will be 
described below.
Role of mitochondria and cholesterol in altered 
cancer cell metabolism
The oncogenic transformation of cancer cells requires 
energy metabolism reprogramming in order to support 
unrestrained growth. The dependence on aerobic gly-
colysis despite normal oxygen tension constitutes one of 
the key metabolic alterations in cancer cells. This event 
was first described by Otto Warburg in 1930 and has 
ben coined since then as the Warburg Effect [96–98]. 
Although the glycolytic phenotype in cancer cells was 
proposed to be due to defective mitochondrial OXPHOS, 
many cancer cells exhibit competent OXPHOS activ-
ity capable to generate ATP [99]. The dependence on 
glycolysis is characteristic of many tumors and is widely 
exploited for clinical tumor imaging using positron emis-
sion tomography (PET) with a radiolabeled analog of 
glucose (18F-fluorodeoxyglucose) [100]. Elevated aerobic 
glycolysis in cancer cells serves many purposes, ensur-
ing ATP generation without reliance on oxygen avail-
ability. Moreover, aerobic glycolysis generates bicarbonic 
and lactic acids, which are released to the extracellu-
lar milieu, favoring tumor invasion, angiogenesis and 
immunosurveillance suppression [101]. Glucose can be 
diverted to the pentose phosphate pathway to generate 
nucleotides and NADPH to fuel antioxidant defenses and 
biosynthetic reactions. Finally cancer cells use interme-
diates of glycolytic pathway for biosynthesis of de novo 
nucleic acids, lipids and amino acids to support their 
unrestrained growth and proliferation [97, 102, 103]. In 
line with these changes, a Warburg-like metabolism has 
been described in many rapidly proliferating embry-
onic tissues, supporting the biosynthetic programs of 
aerobic glycolysis in active proliferating cells [104, 105]. 
Given that many tumor types rely on oxidative metabo-
lism, glucose flux is not necessarily coupled to oxidative 
glucose metabolism. Oxygen consumption in many can-
cer cells is used for mitochondrial oxidation of alternate 
fuels, such as glutamine [106], suggesting that the  fate 
of glucose for mitochondrial oxidation in cancer cells is 
probably even lower. Cancer cells undergo a number of 
metabolic alterations, including the depression of oxida-
tive mitochondrial OXPHOS and TCA cycle, which are 
used for anabolic reactions [107, 108]. Moreover, several 
transcriptional and posttranslational mechanisms have 
been proposed to contribute to the metabolic reprogram-
ming and dependence on the Warburg effect in cancer 
cells, involving activation of oncogenes and inactiva-
tion of tumor suppressor genes. In this regard, activated 
oncogenes such as KRAS and MYC along with mutated 
tumor suppressors such as TP53 can extensively repro-
gram cell metabolism resulting in diversion of carbon 
skeletons to fuel anabolic reactions for biomass synthesis 
instead of being completely oxidized through mitochon-
drial respiration.
MYC in tumor metabolism reprogramming
MYC is an oncogene that plays a role in cell cycle pro-
gression, apoptosis and cellular transformation. In addi-
tion, MYC is important for the increased transcription of 
metabolic enzymes required for anabolism in cancer and 
fast-growing cells, regulating the conversion of glucose 
to pyruvate through the activation of important glyco-
lytic genes and glucose transporters, while blocking the 
entry of pyruvate into the TCA cycle via pyruvate dehy-
drogenase kinase (PDK1). Interestingly, MYC promotes 
the metabolic adaptation of tumor cells [109] by activat-
ing genes important for mitochondrial biogenesis and 
function [110, 111]. Moreover, the AMPK-related pro-
tein kinase 5 (ARK5), which is involved in maintenance 
of mitochondrial integrity and bioenergetic homeosta-
sis, was identified as a MYC target [112]. This dual role 
of MYC as a driver of Warburg effect and a promoter of 
mitochondrial biogenesis underlies the dependence of 
cancer cells on glutamine oxidation, an essential event 
for cell survival under conditions with low glucose and 
oxygen [113]. Moreover, MYC upregulates the glutamine 
transporters SLC5A1 and SLC7A1, which contribute to 
glutamine uptake in cancer cells. As MYC induces the 
flux of 3-phosphoglycerate from glycolysis to the synthe-
sis of serine and glycine needed for nucleotide biosynthe-
sis, MYC coordinates the synthesis of nucleotides with 
glutamine metabolism [114]. Indeed, the rate of glutami-
nolysis is greater compared to the rate of glycolysis in 
cells with high MYC expression and are more dependent 
on mitochondrial oxidative metabolism than cells with 
low MYC levels.
Tumors are metabolically heterogeneous, exhibiting 
complex metabolic profiles [115], including the depend-
ence on aerobic glycolysis and reliance on OXPHOS 
[116–119]. For instance, while cancer stem cells are 
quiescent and exhibit high OXPHOS reliance, they may 
coexist with other highly cycling cancer cells that rely on 
glycolysis. The dependence of these cancer stem cells on 
mitochondrial OXPHOS prompted the use of mitochon-
drial OXPHOS inhibitors to selectively target these cells 
to prevent tumor relapse after cytotoxic treatment [120, 
121]. It has been described that in pancreatic tumors 
MYC acts as a switch between the OXPHOS-dependent 
metabolism of cancer stem cells towards the highly gly-
colytic differentiated progeny, creating a gradient of het-
erogeneous oxidative/glycolytic population inside the 
tumor. Moreover, MYC acts as a direct transcriptional 
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inhibitor of peroxisome proliferator-activated receptor 
α (PGC1-α) suppressing mitochondrial respiration while 
activating glycolytic programs [119]. This heterogeneity 
defines a scenario where therapies targeting specifically 
highly respiratory or highly glycolytic tumor cells may 
not be completely effective.
TP53 and tumor metabolism
Reduced expression of the tumor suppressor protein 
TP53 can also impact metabolic reprogramming in can-
cer cells. Defects in P53 function lead to impaired trans-
activation of SCO2, a mitochondrial protein required 
for the correct assembly of the cytochrome c oxidase 
in the ETC and of TIGAR, an isoform of 6-phospho-
fructo-2-kinase, whose expression exerts a tumor sup-
pressor function by inhibiting glycolytic flux [122, 123]. 
Moreover, TP53 activates transcription of glutaminase 2 
(GLS2) to promote glutaminolysis to fuel the TCA cycle 
and facilitate fatty acid oxidation as an alternative source 
[124]. Collectively, TP53, in addition to its role in orches-
trating cell cycle arrest and apoptosis, counteracts the 
Warburg effect by favoring OXPHOS and minimizing 
glycolytic metabolism, and therefore its loss-of-function 
is a requirement for the aerobic glycolysis in most carci-
nogenic processes.
Hypoxia‑inducible factor (HIF1α)
Hypoxia is an inherent feature of solid tumor develop-
ment that arises due to the disorganized structure and 
architecture of tumor vasculature resulting in irregular 
and inefficient oxygen delivery. Hypoxia is considered a 
negative prognostic factor for response to treatment and 
survival of cancer patients [125, 126]. Hypoxia-induc-
ible factor (HIF) is a key transcription factor activated 
mainly by hypoxia due to the dependence of HIF-proly 
hydroxylases (PHD) on oxygen (see below). In addi-
tion to hypoxia HIF is also regulated by oxidative stress, 
inflammation and metabolic stress [127]. HIF1 com-
prises a stable β subunit (HIF-1β/Arnt) and a labile α 
subunit (HIF1α) encompassing three family members, 
HIF1α, HFI2α and HIF3α (Fig. 1). In normoxia HIF1α is 
rapidly degraded due to the sequential action of oxygen-
dependent PHD and the Von Hippel-Landau E3-ubiq-
uitin ligase (pVHL). PHDs primarily function as oxygen 
sensors so that in normoxia PHDs become activated to 
hydroxylate HIF1α on two highly conserved proline resi-
dues. Hydroxylated HIF1α is then recognized and ubiq-
uitinated by the pVHL, marking HIF1α for proteasomal 
degradation (Fig. 1a). In low oxygen conditions, PHDs are 
inactivated and therefore HIF1α is stabilized, translocate 
to the nucleus where heterodimerize with HIF1β/Arnt to 
form a complex that activates hundreds of genes involved 
in energy metabolism, autophagy and angiogenesis [128] 
(Fig. 1b). Activation of HIF1α promotes the conversion of 
glucose to pyruvate and lactate by upregulating the tran-
scription of glucose transporters (GLUT1), hexokinases 
(HK1 and HK2), lactate dehydrogenase A (LDHA) as well 
as the lactate-extruding monocarboxylate transporter 
4 (MCT4) [129], supporting the shift to aerobic glyco-
lysis. Activated HIF1α increase the transcription of the 
PDK1, which inhibits PDH, decreasing the conversion of 
pyruvate to acetyl-CoA, which compromises OXPHOS, 
therefore linking low oxygen conditions to the depression 
of mitochondrial function. Moreover, HIF-1 activates 
transcription of the cytochrome c oxidase subunit 4-2 
(COX4-2) and the LON mitochondrial protease, which 
degrades COX4-1 subunit and allows its substitution by 
the less efficient COX4-2 subunit [130]. In a scenario with 
inhibited mitochondrial OXPHOS by genetically down-
regulating the master regulator of mitochondrial biogen-
esis PGC1α, ROS-mediated HIF1α stabilization is able 
to rescue cell bioenergetics by activating transcription of 
glycolytic genes and glycolysis, allowing cancer cells to 
escape from metabolic stress [131]. In addition, HIF1 α 
induces the expression of BCL-2/adenovirus E1B 19-kDa 
interacting protein 3 (BNIP3) and BNIP3-like (BNIP3L), 
which trigger mitochondrial autophagy, thereby decreas-
ing the oxidative metabolism of both fatty acids and glu-
cose [132]. Therefore, HIF1α not only counteracts the 
MYC-mediated suppression of mitochondrial biogenesis 
by reducing mitochondrial mass and function, but also 
cooperates with MYC to promote aerobic glycolysis by 
induction of HK2 and PDK1 [133]. There are three PHDs 
known in mammals, encoded by three genes (PHD1, 
PHD2 and PHD3) [134]. Although, PHDs are thought 
to act as true oxygen sensors due to their requirement of 
oxygen for hydroxylation of HIF1, they are also depend-
ent on iron (Fe2+), ascorbate and on the TCA interme-
diate 2-oxoglutarate (2-OG) as cofactors. Conversely, 
it has been reported that several TCA intermediates, 
such as fumarate and succinate competitively inhibit all 
three PHDs, while citrate and oxaloacetate inhibit factor 
inhibiting HIF1 (FIH), an asparaginyl hydroxylase which 
is able to block the transcriptional activity of HIF1α by 
catalyzing the hydroxylation of an asparagine residue of 
HIF1α [135]. These effects have important implications 
as succinate dehydrogenase (SDH) inactivation and isoci-
trate dehydrogenase (IDH) neomorphic gain-of-function 
leading to accumulation of succinate and 2-hydroxyglu-
tarate, respectively, contribute to HIF1α stabilization and 
cancer promotion [136].
Role of ROS in cancer cell biology
The impact of ROS in cancer research is controversial due 
to their dual role in promoting tumor growth, angiogen-
esis and metastasis or supression of tumor development, 
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depending on the context and on the type of species gen-
erated [137–140]. ROS are highly reactive molecules with 
the potential to target and oxidize proteins, lipids and 
DNA, which derive from different sources and mecha-
nisms (Table 2) and from environmental events, such as 
ultraviolet or ionizing radiation [39, 139, 141].
ROS-induced damage on DNA can lead to enhanced 
mutation rates, driving the transformation of normal 
cells into a tumorigenic phenotype. In line with this asso-
ciation, moderate intake of antioxidants have shown to 
reduce the risk of cancer development and slow cancer 
progression [142–145], leading to the concept that anti-
oxidants can prevent ROS-induced damage and there-
fore cancer incidence. Moreover, high ROS production in 
cancer cells can stabilize survival factors such as HIF1α, 
which drive tumor initiation and progression [146]. Solid 
tumor formation, in turn, contributes to hypoxia devel-
opment due to the disorganized vasculature, and the 
limited oxygen supply in solid tumors stimulates mito-
chondrial ROS generation and HIF1α stabilization [147, 
148]. HIF1α in turn activates ROS generation, estab-
lishing a feed-forward loop where HIF1α supports its 
stability to promote cancer cell survival and malignant 
progression [141]. However, transformed cells adapt to 
this oxidative environment by turning on strategies that 
control the generation of ROS to ensure their role in pro-
liferation signaling, while containing the damaging effects 
of ROS overproduction. An important strategy in this 
regard is the modulation of mitochondrial ROS genera-
tion, which is downregulated in cancer cells by shifting 
to aerobic glycolysis. This scenario suggests that reduc-
ing mitochondrial oxidation not only promotes survival 
of cancer cells but also increases anabolic metabolism. 
On the other hand, the pro-apoptotic activity of mito-
chondrial inhibitors are reversed by antioxidants [121, 
149], lending further support for the association of ROS 
with tumor prevention [141]. Conversely, large-scale 
multicenter clinical trials of antioxidant supplementation 
showed a significant increase in cancer incidence [150–
154]. Quite intriguingly recent preclinical studies con-
firmed the pro-tumorigenic and pro-metastatic effects of 
antioxidant supplementation such as N-acetyl-l-cysteine 
(NAC), a GSH precursor [155, 156], thus highlighting the 
relevance of antioxidants in the protection of cancer cells 
against oxidative damage. Therefore, antioxidant supple-
mentation can promote the growth of tumors by rescuing 
the viability of cells under high oxidative stress.
A key survival strategy of cancer cells is the upregula-
tion of antioxidant systems to detoxify the production of 
ROS. One central factor associated to the resistance of 
cancer cells is the transcription factor NF-E2-related fac-
tor (NRF2). NRF2 is a master regulator of the antioxidant 
response and xenobiotic metabolism through the regula-
tion of a wide range of antioxidant and detoxification genes 
[157]. NRF2 is sequestered in the cytoplasm by the Kelch-
like ECH-associated protein 1 (KEAP1), which acts as a 
NRF2 repressor and plays a pivotal role in the regulation 
of the NRF2 pathway. KEAP1 binds and promotes NRF2 
(See figure on previous page.) 
Fig. 1 Regulation of HIF1α transcriptional activity. a In normoxia, PHD hydroxylates HIF1α in several proline and asparagine residues, with 2‑OG, 
ascorbate and Fe3+, acting as cofactors for the reaction. Hydroxyted HIF1α binds with high affinity to the E3 ubiquitin‑ligase pVHL and HIF1α 
becomes ubiquitinated, marking it for proteasomal degradation. Through this mechanism, HIF1α is kept at very low concentrations and transcrip‑
tionally inactive. b In low O2 conditions, the activity of PHD is inhibited due to lack of oxygen, resulted in no hydroxylation nor ubiquitination of 
HIF1α. These events lead to the HIF1α protein stabilization which can translocate to the nucleus where it forms a complex with HIF1β and recruits 
CBP/p300 to the promoter of HIF1α target genes, activating the transcription of a vast array of genes responsible of glycolysis, angiogenesis and cell 
death resistance which are involved in tumor progression
Table 2 Cellular sources of ROS
CIF complex I flavin site, CIQ complex I ubiquinone site, CIIF complex II flavin site 
and CIIIQ0 complex IIIQo are sites of the mitochondrial ETC, mGPDH Mitochondrial 
glycerol 3-phosphate dehydrogenase, ETFQOR electron-trasferring 
flavoprotein ubiquinone oxidoreductase, PDH pyruvate dehydrogenase, 
OGDH 2-oxoglutarate dehydrogenase and BCKDH branched-chain 2-oxoacid 
dehydrogenase are mitochondrial enzymes capable of generate ROS. Upon 
stress signaling, cytosolic p66Shc translocates to mitochondria to directly 
stimulate hydrogen peroxide generation. Nitric oxide synthase (NOS) produces 
NO.by facilitating the conversion of l-arginine to l-citruline. NADPH oxidase 
family of enzymes (NOX) transfer electrons from NADPH to O2 to produce 
O2
−. Other cellular enzymes incuding xanthine oxidase and cytochrome p450 
families also participate in ROS generation in normal biological reactions and in 
chemicals or xenobiotics detoxification reactions




Complex IF Mitochondria O2−
Complex IQ Mitochondria O2−
Complex IIF Mitochondria O2−






P66shc Mitochondria, cytoplasm H2O2
NOS Cytoplasm NO
NOX family Cytoplasm, cell membrane O2−
Xantine oxidase Cytoplasm, peroxisome H2O2
Cytochrome p450 family Endoplasmic reticulum O2−
H2O2
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degradation through the ubiquitin–proteasome path-
way. Under oxidative stress or through particular chemi-
cal inducers, cysteine residues of KEAP1 are modified and 
the resulting conformational change leads to the release of 
NRF2, which is stabilized and translocated to the nucleus, 
to induce the transcription of a large number of genes 
[158]. In this regard, NRF2 activators, such as curcumin, 
butylated hydroxyanisole (BHA) or the synthetic oleane 
triterpenoids (CDDO), have preventive properties against 
carcinogenesis [157]. However, given the dual role of ROS 
on cancer genesis and development, NRF2 activation 
also provides protection to cancer cells. Therefore, NRF2 
is constitutively elevated in many types of cancer cells 
[159–162] and this increase is associated with a poor prog-
nosis in cancer patients [163–165]. A variety of molecular 
mechanisms contribute to the constitutive expression and/
or stabilization of NRF2 in cancer cells. Loss-of-function 
by somatic mutations or epigenetic silencing of KEAP1 
impairs its binding to NRF2 and abrogates its repres-
sive effect [159, 166]. The autophagy protein P62, also 
named sequestrosome 1, binds and sequesters KEAP1 in 
autophagosomes, leading to the autophagy-dependent 
KEAP1 degradation, resulting in increased NRF2 stability 
and activation of target genes [167–170]. Overexpression 
of P62 or increased P62 levels due to defects in autophagy 
leads to persistent activation of NRF2 [171, 172], contrib-
uting to carcinogenesis [173]. In addition, activation of 
oncogenes such as K-RAS, BRAF and MYC stimulates 
the transcription of NRF2 [174]. There is substantial evi-
dence that impaired TCA cycle activates NRF2 [175], in a 
similar fashion as described for HIF1α. In this case, fuma-
rate accumulation can form adducts with KEAP1 on its 
cysteine residues and provoke NRF2 activation. Physiolog-
ical fumarate levels are low due to the activity of fumarate 
hydratase (FH). However, in cancer cells with loss-of-func-
tion of FH, high levels of fumarate are associated with sus-
tained NRF2 activation [176, 177]. Nonetheless, activation 
of NRF2 transcriptional activity leads to the upregulation 
of antioxidants and detoxifying enzymes that promote not 
only the survival of cancer cells but also mediate chem-
oresistance [178, 179]. Besides these important roles of 
NRF2 on detoxification, it has also been shown that NRF2 
can contribute to other aspects of cancer survival such as 
the counteraction of cell death by BCL-2 overexpression 
[180] and altered metabolism by redirecting glucose and 
glutamine to the production of ribose-5-phosphate for 
nucleotide synthesis and to the regeneration of NADPH 
through the activation of the pentose-phosphate pathway 
[181].
Besides the role of ROS scavenging in cancer progres-
sion, this event is also important for cancer metastasis. 
Hence, it can be postulated that the supplementation 
of antioxidants would provide an additional advantage 
for cancer cells to spread to distant sites by counter-
acting their sensitivity to anoikis and oxidative stress. 
For instance, metastatic cells undergo reversible meta-
bolic changes that allow them to counteract oxidative 
stress [156, 181]. Indeed, it has been recently shown 
that increased GSH synthesis mediates the metastatic 
colonization of colorectal cancer cells to the liver [182]. 
Conversely, other reports showed that inhibition of mito-
chondrial oxidative stress prevents metastasis [183, 184] 
and this apparent paradox might be explained by the dif-
ferent targets of antioxidants and their effect in different 
types of cancer cells [184–186]. Therefore, current anti-
oxidant strategies are not clinically effective in cancer 
therapies, illustrating our limited understanding on the 
complex role of ROS in tumor initiation, progression and 
metastasis, which needs to be fully characterized to iden-
tify new and more effective therapeutic venues.
Mitochondrial cholesterol in HIF1α regulation
As mentioned above, HIF-1 is the main transcription 
factor regulating the cellular response to hypoxia and 
its stabilization is known to promote cell survival and 
tumor progression. While HIF-1 stabilization is mainly 
determined through oxygen sensing by PHD and iron 
availability, PHD activity is also dependent on the cyto-
solic levels of 2-OG. Indeed, 2-OG emerges as a potential 
inhibitor of angiogenesis and cellular transformation by 
promoting the degradation of HIF1 [187, 188].
HIF-1α activation contributes to the metabolic repro-
gramming of cancer cells by impairing mitochondrial 
phosphorylation and the subsequent stimulation of 
aerobic glycolysis. Although the physiological levels of 
mitochondrial cholesterol are low, mitochondrial cho-
lesterol accumulation impairs mitochondrial function 
and the activity of the mitochondrial 2-oxoglutarate car-
rier (2-OGC), which exchanges cytosolic GSH by matrix 
2-OG. As StARD1 promotes mitochondrial cholesterol 
accumulation in the inner membrane, StARD1 induc-
tion thus contributes to the impairment of OGC car-
rier, resulting in the depletion of 2-OG in the cytosol 
and GSH in the mitochondrial matrix (Fig.  2). As men-
tioned above, mGSH is a key mitochondrial antioxidant 
that controls hydrogen peroxide production [39, 189, 
190]. Moreover, mitochondrial ROS generation has been 
shown to promote HIF-1 α stabilization [147, 191]. Thus, 
it is conceivable that StARD1 induction and the subse-
quent accumulation of cholesterol in mitochondria result 
in the depletion of cytosolic 2-OG, impairing PHD acti-
vation and subsequent HIF-1α stabilization. Therefore, 
mitochondrial cholesterol loading may have an impor-
tant role in cancer cell survival by a dual effect through 
impairment in mitochondrial function and dynamics, 
while promoting HIF1α stabilization via depletion of 
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cytosolic 2-OG levels and generation of mitochondrial 
ROS. As a result, mitochondrial cholesterol loading in 
cancer cells acts as an additional mechanism governing 
angiogenesis and novel vessel growth via HIF1α stabiliza-
tion, although this molecular link deserves to be further 
tested and it is currently under investigation. Finally, his-
tone lysine demethylases have been recognized as impor-
tant players in cancer cell biology by removing methyl 
moieties from DNA and aberrant expression of these 
chromatin modifying enzymes is implicated in the course 
of tumor initiation and progression [192]. Like PHD, his-
tone methyl demethylases are also dependent on iron and 
2-OG, and therefore mitochondrial cholesterol loading 
may further modulate cancer progression by the regula-
tion of histone lysine demethylases via limitation of cyto-
solic 2-OG levels, which deserves further investigation.
Role of mitochondria and cholesterol in cancer cell 
death and chemotherapy resistance
Mitochondria and cell death resistance
Cancer cells have evolved multiple mechanisms to disable 
programmed cell death to support their survival and pro-
liferation. Given that mitochondria are key players in sev-
eral pathways of programmed cell death (see above) many 
strategic battles regulating cell death resistance take place 
in mitochondria [49]. The most prominent example of 
this is the overexpression of pro-survival BCL-2 proteins, 
a common feature in diverse cancers. The gene encoding 
BCL-2 was first identified in a chromosomal transloca-
tion that resulted in constitutively high levels of BCL-2 in 
neoplastic B cells [193, 194]. Different mechanisms such 
as genomic copy number amplification, oncogenic tran-
scriptional upregulation or downregulation of microRNA 
repressors or stabilization of BCL-2 family members con-
tribute to the maintenance of high levels of Bcl-2 [195, 
196]. On the other hand, due to genomic deletion or pro-
moter methylation leading to transcriptional silencing, 
loss-of-function of several pro-apoptotic proteins such 
as BAK, BAX and BH3-only family members have been 
observed in a variety of cancer types. Although BAX and 
BAK can play redundant roles, recent experimental data 
argues that in the context of activation of BH3-only pro-
tein or anti-apoptotic BCL-2 there is a strict dependence 
of either BAX or BAK [197, 198]. Although cancer cells 
are generally resistant to apoptosis, certain stress condi-
tions, such as hypoxia and low nutrient availability, lower 
the threshold for apoptosis susceptibility. Cancer cells 
often exhibit higher levels of pro-apoptotic BH3-only 
protein, which is accompanied by higher anti-apoptotic 
BCL-2 proteins to antagonize apoptosis. This state has 
been termed as cancer cells “primed for death” [199] and 
this dependence on anti-apoptotic BCL-2 proteins can be 
Fig. 2 Mitochondrial cholesterol‑mediated HIF1α stabilization. Mitochondrial cholesterol loading mediated by StARD1 decreases mitochon‑
drial membrane fluidity which leads to an impaired activity of the OGC, which exchanges mitochondrial 2‑OG by cytosolic GSH. Cytosolic 2‑OG 
depletion may promote HIF1α stabilization by the impairment of PHD due to their requirement of 2‑OG as a cofactor for HIF1α hydroxylation and 
subsequent degradation. Moreover, 2‑OGC inhibition results in mGSH depletion, which in turn, limits the detoxification of ROS, in particular, H2O2. 
The subsequent increase in ROS and oxidative stress impact negatively on PHD, resulting in HIF1α stabilization
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exploited to design more effective pro-apoptotic thera-
peutic strategies [200].
Loss–of-function of TP53 is found in more than 50 % 
of human cancers. In addition to the above-mentioned 
roles of its inactivation in cancer cell metabolism, TP53 is 
central in the orchestration of cell death pathways upon 
cellular stress such as DNA damage by stimulating the 
transcription of pro-apoptotic proteins (PUMA, BAX), 
autophagy and cell-cycle arrest. TP53 exerts a vast array 
of extranuclear functions and therefore the cytoplasmic 
pool of TP53 cooperates with its nuclear counterpart 
to activate programmed cell death in response to cer-
tain cellular stresses. TP53 is involved in various forms 
of cell death such as apoptosis, necrosis and necroptosis 
and is able to mediate both MOMP and MPT opening in 
response to death stimuli. After stress induced TP53 acti-
vation, a small fraction translocates to MOM, resulting 
in the activation of the intrinsic apoptotic pathway [201]. 
TP53-mediated MOMP is related to the ability to bind 
and inactivate anti-apoptotic BCL-2 and BCL-xL, and to 
transcriptionally induce the expression and activation of 
pro-apoptotic proteins by direct binding [202]. Moreover, 
TP53 regulates MPT openings of necrosis/necroptosis 
via cyclophillin D and dynamin-related protein 1 (DRP1) 
[203, 204] in response to specific cell death triggers, such 
as TNFα or oxidative stress. In addition, TP53 inhibits 
autophagy [205], resulting in impaired mitophagy, con-
tributing to the reduced threshold for cell death. Given 
these protective roles against specific alterations in cell 
cycle and cell death resistance, many cancer-associated 
TP53 mutations have been identified. Although most of 
TP53 mutations has been described as loss-of-function, 
it has been proposed that some TP53 mutations may 
have oncogenic capabilities [206].
Although MOMP is considered a point of no return 
for apoptosis, cancer cells are able to inhibit caspases 
ensuring survival in certain conditions. This mechanism 
described in some post-mitotic cells, such as neurons 
and certain cancer cells, allows the recovery of cancer 
cells provided that MOMP-inducing stimuli are removed 
[207–209]. Caspases can be directly inhibited by XIAP or 
by the neutralization of its inhibitors [200]. In addition, 
cytochrome c released through MOMP can be targeted 
for proteasomal degradation thereby avoiding the assem-
bly of the apoptosome [209]. Besides caspase inhibition, 
survival after MOMP requires a pool of intact mitochon-
dria in which MOMP has not been triggered [210]. The 
selective maintenance of cells with intact mitochondria 
may contribute to carcinogenesis and cancer relapse 
after cytotoxic therapies due to the increased susceptibil-
ity to oncogenic transformation [211]. Moreover, limited 
mitochondrial permeabilization induced by sub-lethal 
apoptosis triggers can promote DNA damage, genomic 
instability and ultimately carcinogenesis [212, 213]. This 
mechanism would have two important implications for 
cancer progression. First, low-level limited apoptosis can 
drive mutagenesis in surviving cancer cells, serving as a 
driving force towards malignancy. Second, sub-lethal 
apoptotic anticancer therapies can increase the tumo-
rigenic potential of surviving cancer cells by promot-
ing new mutations that favor relapse and chemotherapy 
resistance.
Mitochondrial cholesterol in cell death and chemotherapy 
resistance
As mentioned above, cholesterol trafficking to mitochon-
dria has been reported in tumor cells, including mito-
chondria from HCC due to overexpression of StARD1 
[17]. Mitochondrial cholesterol loading in cancer cells 
may account for the recognized mitochondrial dysfunc-
tion and resistance to BAX-mediated cell death induced 
by chemotherapeutic agents that target mitochon-
dria to elicit MOMP. In line with this, treatments that 
resulted in mitochondrial cholesterol loading in tumor 
cells impaired stress-induced apoptosis [17, 18], while 
StARD1 knockdown or treatments that resulted in down-
regulation of cholesterol loading sensitized HCC cells to 
chemotherapy [17]. Isolated mitochondria from HCC 
with increased cholesterol levels have been reported to 
be resistant to MOMP and release of cytochrome c or 
smac/DIABLO in response to various stimuli, such as 
MPT triggers and active BAX. In agreement with these 
findings, HeLa cells treated with the amphiphilic amine 
U18666, which perturbs intracellular cholesterol traffick-
ing and stimulates mitochondrial cholesterol accumula-
tion, impairs MOMP and the release of cytochrome c in 
response to BAX [18]. Furthermore, ABCA1 downregu-
lation determines resistance to chemotherapy through 
increased mitochondrial cholesterol accumulation [95]. 
Similar behavior was observed in cholesterol-enriched 
mitochondria or liposomes and reversed by restoring 
mitochondrial membrane order or cholesterol extrac-
tion. Cholesterol inhibited the membrane-permeabiliz-
ing activity of tBID/BAX or BAX pre-oligomerized with 
octylglucoside in a dose-dependent manner. Similar 
to the effect found on BAX, cholesterol also decreased 
the permeabilizing activity of melittin, a widely studied 
antimicrobial peptide, which induces membrane per-
meabilization by forming lipid-containing toroidal pores 
rather than through the formation of protein channels 
[17]. These findings indicate that cholesterol-mediated 
decrease in membrane fluidity of the bilayer directly 
modulates BAX pro-apoptotic activity by reducing the 
capacity of BAX to insert into the lipid matrix of the 
membrane, underlying the anti-apoptotic role of mito-
chondrial cholesterol accumulation in cancer cells. Thus, 
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mitochondrial cholesterol contributes to chemotherapy 
resistance in HCC by increasing membrane order and 
resistance of MOM to MOMP. As StARD1 regulates 
mitochondrial cholesterol trafficking, it is conceivable 
that this member of the StART family stands as a novel 
target to regulate cancer cell death and chemotherapy 
response.
Cancer biology and therapeutics
As described in the previous sections, cancer cells exhibit 
critical metabolic transformations induced by muta-
tions that result in cell cycle deregulation associated 
with enhanced cellular stress. Adaptation to this stress 
phenotype is required for cancer cells to survive and 
involves the participation of genes that regulate metab-
olism, bioenergetics, cell death and ROS detoxification 
(Fig.  3). In this context, small molecules that selectively 
kill cancer cells while sparing normal surrounding cells, 
are the desired approach for the treatment of cancer. To 
this aim, cancer therapeutics should target the differen-
tial features of cancer cells. Here, we briefly summarize 
the therapeutic strategies that involve mitochondria and 
their proposed mechanism of action to selectively target 
transformed cells.
Therapeutics aimed at cancer metabolism 
and bioenergetics
Cells are addictive to glucose and glutamine and their 
limitation can cause cell death. This dependence is 
driven by the activation of MYC and HIF1-α [109] and 
consequently, targeting pathways regulating glucose/
glutamine metabolism may be of relevance for cancer 
a c
b d
Fig. 3 General summary of altered mitochondrial functions in cancer cell life and death. a In normal non‑transformed cells glucose is mainly 
metabolized through the glycolysis pathway and the resulting pyruvate enters the mitochondrial TCA cycle, producing reduced equivalents that are 
fed into the ETC to generate ATP with high efficiency through the OXPHOS. Antioxidant defenses and coupled respiration through OXPHOS main‑
tain low levels of mitochondrial ROS. b Normal cells are sensitive to apoptotic stimuli triggered by different stresses that finally converge in BAK/
BAX activation and MOMP with subsequent release of cytochrome c into the cytosol, stimulating the formation of the apoptosome and apoptotic 
cell death. c In cancer cells gain‑of‑function of oncogenes and loss‑of‑function of tumor suppressor genes (such as MYC, HIF1α and TP53) results in 
altered metabolism, exemplified by the Warburg effect, characterized by high glucose consumption rates. Glucose is degraded through glycolysis to 
obtain biosynthetic intermediates and the resulting pyruvate is reduced to lactate to generate ATP. In this scenario, mitochondrial TCA is diverted to 
generate biosynthetic intermediates, which is accompanied by low OXPHOS activity and increased mitochondrial ROS production. NRF2 is upregu‑
lated in cancer cells to counteract ROS and permits cancer cells to withstand its deleterious effects. d Cancer cells, through the overexpression of 
anti‑apoptotic proteins or inactivation of pro‑apoptotic proteins, counteract the action of BAX/BAK and evade MOMP formation. Besides this effect, 
mitochondrial cholesterol loading shields mitochondrial membrane, impairing BAK/BAX oligomerization in MOM and subsequent MOMP formation 
and represents an additional mechanism of cell death resistance in tumor cells
Page 14 of 24Ribas et al. Clin Trans Med  (2016) 5:22 
treatment. The specific GLS1 inhibitor bis-2-(5-pheny-
lacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) 
inhibits proliferation of lymphoma cells but has no effect 
on neuroblastoma cells, which express GLS2 [214, 215], 
implying that the general GLS inhibitor 6-diazo-5-oxo-L-
norleucine (DON) may exhibit broader antitumor effects 
[216, 217]. Inhibitors of glutamate dehydrogenase (GDH) 
are promising agents to target glutamine addiction of 
certain cancer cells. For instance, the green tea compo-
nent epigallocatechin-3-gallate (EGCG), which inhibits 
GDH, has been shown to promote apoptosis in several 
cancers types, resulting in tumor growth inhibition, set-
ting the basis for the exploration of its efficacy in phase II 
clinical trials [214, 218].
The inhibition of aerobic glycolysis in cancer cells is 
also of potential relevance. While inhibitors such as 
2-deoxy-d-glucose and ionidamine, which targets early 
steps in the glycolysis pathway, exhibit severe toxic side 
effects [218], inhibition of distal steps in glycolysis are 
effective. Inhibition of lactate production by inactivation 
of lactate dehydrogenase (LDH) reduces tumorigenic-
ity in several cancer models [219–221]. Additionally, 
the specific inhibitor of LDHA, FX11, reduces tumor 
progression in lymphoma in vivo [219]. In some cancers 
LDHB can replace LDHA, hence limiting the efficacy 
of the LDHA inhibitors [109, 222]. Inhibition of lactate 
export from cancer cells results in wide-reaching con-
sequences, leading not only to lactate accumulation, 
alterations in glycolytic intermediates, reduction in glu-
cose transport and ATP, NADP and GSH levels but also 
in mitochondrial damage and cell death [223], suggest-
ing that inhibition of lactate transporter MCT1 is a suit-
able therapeutic approach. Moreover, the effect of small 
molecules that block the entry of pyruvate to the mito-
chondrial TCA cycle, such as dichloroacetate, a PDK1 
inhibitor, may be of potential relevance [109, 218, 224].
Although targeting glycosis may be effective in a spe-
cific population of cancer cells exhibiting a highly glyco-
lytic dependence, stem cancer cells that rely on OXPHOS 
might become resistant. Moreover, although mitochon-
drial oxidation under the Warburg effect is dramatically 
reduced, many cancer cells still have a central require-
ment on mitochondrial metabolism, strongly suggesting 
that OXPHOS inhibitors might represent an important 
target for drug-resistant cancers [121]. A key agent with 
potential relevance in inhibiting OXPHOS is metformin, 
one of the most prescribed drugs around the world for 
the treatment of type II diabetes [225–228]. Metformin 
is an indirect activator of AMP-activated Kinase (AMPK) 
through inhibition of mitochondrial complex I, result-
ing in the activation of the ATM/LKB1/AMPK axis. 
LKB1 is a well-characterized tumor suppressor in pan-
creatic, lung cancer and melanoma. AMPK activation 
inhibits the mTOR pathway and this effect accounts for 
the potential antineoplastic effects of metformin in breast 
and renal tumors. Moreover, metformin reduces glyco-
lysis and increases mitochondrial respiration in tumors, 
and these events are associated with growth arrest [229]. 
In addition, metformin exhibits antiangiogenic effects, 
which contribute to its antineoplastic properties [230]. 
Other compounds with mild OXPHOS inhibition such 
as tamoxifen, which also inhibits complex I, resveratrol, 
which antagonizes complex III, and the complex V inhib-
itor 3,3-diindolylmethane have potential in cancer treat-
ment. VLX600 is a novel compound targeting OXPHOS 
that inhibits tumor growth of colon carcinoma cells, thus 
exhibiting potential application in clinical trials [231]. 
Besides, a number of emerging mitochondrial inhibitors 
successfully used in experimental studies could be effec-
tive against cancer cells and might synergize with chemo-
therapeutics [149, 232, 233].
Therapeutics targeting cancer cell death
Given that BCL-2 is overexpressed in many tumors, most 
strategies to engage apoptosis pathways are based in the 
blockade of anti-apoptotic members of the BCL-2 fam-
ily. BCL-2 inhibitors have been developed based on the 
structure of BH3-binding groove of BCL-xL [234], lead-
ing to the development of the prototypic BH3 mimetic 
that displays sub-nanomolar affinity for BCL-xL and a 
binding profile similar to the BH3-only protein BAD. The 
BH3 mimetic ABT-737 and the more soluble analogue 
ABT-263 bind BCL-xL, BCL-2 but not MCL1 and both 
show antitumor activities either as single agents or in 
combination [235]. However, the clinical applicability of 
these BH3 mimetics is limited due to severe thrombocy-
topenia mediated by platelet apoptosis [236, 237]. ABT-
199, a novel BH3 mimetic developed from the structure 
of ABT-263 [238], is effective in chronic lymphocyte leu-
kemia. A potential side effect of ABT-199 is the induction 
of tumor lysis syndrome [239], which can be controled 
by step-wise dose escalation. Although the therapeutic 
results with BH3 mimetics are promising, resistance is a 
potential drawback. For instance, BCL-2 mutations that 
abrogated binding of BH3 mimetics mediate resistance 
of ABT-199 in experimental lymphoma models [240]. As 
BCL-2 inhibitors do not target MCL-1, a key anti-apop-
totic BCL-2 member, the efficiency of BH3 mimetics may 
be limited, particularly in the treatment of solid tumors 
[241–243]. Hence, the combination of specific MCL1 
inhibitors [244, 245] with BH3 mimetics is a promising 
therapeutic approach to overcome chemotherapy resist-
ance. Moreover, as MCL-1 plays a key role in mitochon-
drial physiology and autophagy, targeting MCL-1 may 
cause undesirable side effects [246, 247]. For instance, 
the toxicity of pan-BCL-2 inhibitors, such as Gossypol or 
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Obatoclax, which inhibit BCL-2 and MCL1, prevented 
the evaluation of their efficacy in clinical settings [243]. 
These findings suggest that MCL1 inhibition should be 
fine-tuned and that the relative contribution of BCL-
2-family components to the apoptosis resistance of can-
cer cells should be carefully evaluated through the “BH3 
profiling” to determine the therapeutic window [248, 
249]. In addition, incomplete cell death caused by trig-
gers of mitochondrial apoptosis can promote genomic 
instability and mutagenesis derived from the incomplete 
MOMP and caspase-dependent DNA cleavage, contrib-
uting to tumor relapse and the acquisition of drug resist-
ance [212, 213]. Based on the ability of TP53 to induce 
apoptosis, mitochondrial targeted TP53 fusion proteins 
have been developed to induce intrinsic apoptosis in can-
cer cells, which may be of relevance in adjuvant therapy 
for cancer treatment [201, 250]. Overall, targeting or sen-
sitizing cancer cells to apoptosis is a promising strategy 
currently under development, which may lead to per-
sonalized medicine through specific tumor-profiling and 
fine-tuning dosage and therapy combinations.
Therapeutics targeting cancer cell ROS sensitivity
Despite generation of higher ROS levels cancer cells 
are more sensitive to intracellular ROS induction than 
untransformed cancer cells. Many cancer chemothera-
peutic agents, including taxanes, vinca alkaloids, plati-
num coordination complexes, paclitaxel and elesclomol 
are currently used to induce high levels of ROS to kill 
cancer cells [251]. The ultimate effect of these molecules 
is determined by the intrinsic antioxidant capacity of 
cancer cells as the cytotoxic potential of these agents is 
lost upon antioxidant co-treatment [252–254].
A key mechanism to counteract the generation of ROS 
by chemotherapeutic agents is the regulation of GSH 
homeostasis [137, 182]. Several small molecules, which 
modulate ROS, such as β-phenethyl isothiocyanate 
(PEITC), buthionine sulphoximine (BSO), curcumin or 
CDDO derivatives, have potential therapeutic effects for 
the treatment of cancer by promoting mGSH deletion 
and subsequent ROS generation specifically in cancer 
cells [255–258]. BSO, an inhibitor of glutamate-cysteine 
ligase, which is the rate-limiting enzyme in GSH biosyn-
thesis [259] is the only clinically used drug to suppress the 
novo GSH synthesis. The simultaneous administration 
of BSO and the thioredoxin inhibitor auranofin induce 
ROS and clonogenic killing in carcinoma cells [260]. Sul-
fasalazine, which inhibits cystine uptake via XcL carrier, 
limits cysteine availability impairing GSH biosynthesis, 
which leads to reduced growth and viability of cancer 
cells in vitro and in vivo [261, 262]. In addition, specific 
mGSH depletion has also been associated with apopto-
sis induced by chemotherapeutic drugs. For example, 
the triterpenoid methyl CDDO derivative (CDDO-Me), 
induces cytotoxicity in chemotherapy-resistant myeloid 
leukemia cells and this event is associated with selective 
depletion of mGSH, resulting in increased ROS genera-
tion [263, 264]. Moreover, PEITC depletes mGSH and 
consequently increases ROS and nitric oxide, contribut-
ing to inhibition of the mitochondrial complex I, sup-
pression of mitochondrial respiration, and subsequent 
cytotoxicity of leukemia cells [265]. Using a cell-based 
small-molecule screening and quantitative proteomics, 
piperlongumine has emerged as a cytotoxic agent that 
triggers apoptosis and necrosis in leukemia cells [266]. 
Interestingly, piperlongumine induces ROS generation 
and cell death in transformed cells but not primary nor-
mal cells [267]. Piperlongumine also decreases GSH and 
increases GSSG levels in cancer cells without effects in 
nontransformed cells, and these effects parallel the abil-
ity of piperlongumine to alter mitochondrial morphology 
and function. Consequently, co-treatment with piperlon-
gumine and NAC prevented piperlongumine-mediated 
GSH depletion and cell death in cancer cells. These find-
ings support the concept that cancer cells have high lev-
els of ROS, and hence, have a strong reliance on the ROS 
stress-response pathway driven by NRF2.
At present, radiotherapy is widely used in various types 
of cancer treatments, and the therapeutic effect is mainly 
determined by ROS generation. The induction of water 
radiolysis occurs in seconds after ionizing radiation, lasts 
several hours after exposure and enhances ROS genera-
tion and oxidative stress [268, 269]. Some studies sug-
gested that antioxidant supplementation could sensitize 
cancer cells to chemo- or radio-therapy and reduce their 
side effects by protecting the normal cells [270]. How-
ever, other studies indicated that antioxidants may also 
protect cancer cells against these therapies [252, 271, 
272]. Therefore, the safety and efficacy of the combined 
treatment of antioxidants with radiotherapy or ROS-
inducing chemotherapy remain controversial.
Strategies targeting the mevalonate pathway 
and cholesterol synthesis in cancer
As described above, cancer cells exhibit alterations in the 
regulation of cholesterol homeostasis and de novo syn-
thesis in the mevalonate pathway. Despite that the main 
therapeutic benefit of statins is the prevention of cardio-
vascular diseases and heart attacks, the use of statins has 
been associated with lower incidence of colorectal car-
cinoma, melanoma, prostate cancer and HCC, although 
the benefit of statins in other types of cancer has been 
disappointing [273]. While statins inhibit cholesterol syn-
thesis, they also affect other intermediates of the meva-
lonate pathway, including isoprenoids, and therefore the 
beneficial effects of statins in cancer may be independent 
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of cholesterol synthesis. For instance, statins inhibit the 
activation of the proteasome pathway, contributing to the 
maintenance of proteins that block cell cycle. Through 
cholesterol downregulation, statins regulate the function 
of Hedgehog, a signaling pathway involved in carcinogen-
esis [273]. Besides these wide-reaching effects of statins, 
their benefit in cancer treatment is limited due to the 
complex regulation of HMGCoAR and the metabolites 
generated in the mevalonate pathway. Reduction of iso-
prenoid and cholesterol levels in cancer by chronic treat-
ment with statins leads to upregulation of HMG-CoAR 
levels and eventually development of resistance [274]. 
In  vitro mechanistic studies of statins used significantly 
higher concentrations than those that were therapeuti-
cally achievable in phase I trials. Dose-limiting toxici-
ties, including gastrointestinal side effects, myelotoxicity, 
myalgias, elevation of creatine phosphokinase and hepa-
totoxicity, precluded further dose increase in clinical tri-
als [275]. Inhibition of SS has attracted much interest as 
a pharmacological target as it implies the inhibition of 
cholesterol synthesis without depressing isoprenoid lev-
els. For instance, lapaquistat (TAK-475, Takeda), a SS 
inhibitor, progressed to phase III clinical trials, although 
its outcome in cancer remains to be established due to 
hepatotoxic effects at high dosing [276]. As mentioned 
before, prenylation is a key postranslational mechanism 
of targeted proteins, and many prenylated proteins are 
involved in various aspects of carcinogenesis, including 
cellular proliferation, apoptosis, angiogenesis and metas-
tasis. Farnesylation is catalyzed by farnesyltransferase 
(FTase) and geranylgeranylation by geranylgeranyltrans-
ferase, GGTase. Given the role of protein prenylation 
in carcinogenesis, FTase inhibitors (FTIs) and GGTase 
inhibitors (GGTIs) have been developed for cancer treat-
ment. GGTI–FTI combinations synergistically inhibit 
proliferation of multiple myeloma cell lines and primary 
cells, and induce apoptosis. Interestingly, dual prenyla-
tion inhibitors (DPIs) that block both FTase and GGTase 
enzymatic activities have been shown to induce apoptosis 
in PSN-1 pancreatic tumor cells by blocking K-Ras pre-
nylation compared to either FTI or GGTI agents alone 
[277]. H and N-Ras prenynation is effectively inhibited 
by FTIs and only partially by GGTIs, whereas K-Ras pre-
nylation requires both FTIs and GGTIs inhibition [278]. 
Thus, combined inhibition of geranylgeranylation and 
farnesylation can overcome the resistance conferred by 
cross-prenylation, thus potentiating the activity of either 
FTIs or GGTIs alone. Finally, targeting the specific tar-
geting of cholesterol to mitochondria may be an addi-
tional approach of potential benefit in cancer treatment 
by modulating cell death and chemotherapy resistance. 
This specific field is currently under investigation to iden-
tify potential specific inhibitors of StARD1 and MLN64 
to sensitize cancer cells to cell death triggers and chem-
oterapeutic agents.
Conclusions and future approaches
Cancer cells undergo an array of genetic and epigenetic 
modifications that lead to a phenotype characterized 
by high proliferation, death resistance, rapid growth 
and invasiveness. Mitochondria play an essential role 
in metabolism, bioenergetics and cell death regulation 
and consequently oncogenic modifications characteris-
tic of many cancer types mediate the array of metabolic 
alterations of cancer cells by impairing key mitochon-
drial functions. This continuum evolving process in the 
adquisition of a highly proliferative phenotype requires 
the selection of cells with decreased mitochondrial oxi-
dation of fuels, relying on the oxidation of glucose for 
ATP generation, resulting secondarily in the engage-
ment of the pentose phosphate pathway as a source of 
reducing equivalents needed for anabolism and antioxi-
dant defense. These metabolic alterations are accompa-
nied by the involvement of mitochondria in biosynthetic 
pathways to support continuous growth, while reducing 
the deleterious effects of high-rate production of ROS, 
a characteristic feature of cancer cells. Furthermore, 
mitochondria undergo changes in membrane dynam-
ics, exemplified by the decrease in membrane fluidity to 
protect cancer cells against the induction of programmed 
cell death triggered by the immune system or by meta-
bolic or xenobiotic stresses. A key player in this event is 
the accumulation of cholesterol in mitochondria of can-
cer cells, which increases the threshold for MOMP by 
restructuring mitochondrial membrane bilayers. Besides 
this function, mitochondrial cholesterol accumulation 
may indirectly contribute to the metabolic changes of 
cancer cells by impairing mitochondria function and acti-
vation of survival programs turned on by HIF1α activa-
tion. Given these functions of mitochondrial cholesterol, 
preventing or reversing this process may be of rele-
vance in cancer cell biology to shift the balance towards 
increased apoptosis susceptibility and sensitization to 
chemotherapy. In addition, oncogenes, transcription fac-
tors (e.g. MYC, HIF1α, NRF2) and inactivation of tumor 
suppressors, such as TP53, allow invasiveness and chem-
oresistance, in part, by regulating mitochondrial function 
and metabolism as well as by controling the outcome of 
ROS generation. Metabolic stress, immune surveillance 
and chemotherapy act as a selective pressure that allows 
only the survival of cells with specific features, driving 
cancer cells towards a highly glycolytic, apoptosis-incom-
petent and invasive phenotype. Given the complexity in 
the metabolic alterations of cancer cells mediated largely 
through alterations in mitochondrial function, further 
research is required to identify more efficient strategies 
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for cancer treatment involving the use of small molecules 
targeting mitochondrial metabolism.
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